The incoming employees at the biopharmaceutical giant will zero in on mRNA, structural biology, and viral vaccine research ...
Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...
PHOENIX — Arizona is suing a major drug maker, accusing it of gaming the system by simply renaming an asthma drug to allow it ...
Arizona is suing a major drug maker, accusing it of gaming the system by simply renaming an asthma drug to increase its ...
The state’s top lawyer accused a British multinational drug company of “deceptive and unfair practices” that endangered lives and exploited American taxpayers.
GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...
American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...
CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...
GSK lifts long-term sales targets on new drug pipeline - It came as the boss of the London-listed firm cheered an ‘excellent’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results